MCP-1 in psoriatic patients: effect of biological therapy
MCP-1 in psoriatic patients: effect of biological therapy
复制标题
DOI：
10.3109/09546634.2013.782091
复制
发表时间：
2014-02-01
影响因子：
2.9
通讯作者：
Ayala, Fabio
中科院分区：
文献类型：
--
作者：
Lembo, Serena;Capasso, Rosanna;Ayala, Fabio
背景：单核细胞趋化蛋白-1 (MCP-1) 是一种在银屑病中局部和全身增强的趋化因子。 MCP-1 启动子区 -2518A -> G 中的单核苷酸多态性与较高的基因表达相关。目的：目的是评估银屑病患者的 MCP-1 血浆水平，并将血浆和皮肤 MCP-1 与生物药物引起的临床改善之间的关联联系起来。方法：从以下部位采集血样：(i) 30 名白人银屑病患者和 10 名对照者，用于测定 MCP-1 血浆浓度和 -2518A -> G 多态性发生情况；(ii) 16 名接受抗肿瘤坏死因子-α (TNF-α) 阿达木单抗/依那西普或抗 CD-11 依法珠单抗治疗的银屑病患者，治疗前和治疗 2 个月后。此外，对 5 名接受抗 TNF-α 治疗的患者的病变皮肤进行了活检。通过 ELISA 和 qRT-PCR 测定 MCP-1 血浆浓度和皮肤表达。结果：银屑病患者血浆MCP-1水平显着升高。 -2518A -> G 多态性在患者和对照中分布相似，与 MCP-1 血浆水平或银屑病面积和严重指数无关。所有接受生物药物治疗的患者均表现出显着的临床改善。抗TNF-α治疗适度降低MCP-1血浆浓度并大幅降低病变皮肤中MCP-1的表达。结论：MCP-1 应该是银屑病患者潜在的局部炎症标志物，用于评估疾病严重程度和抗 TNF-α 治疗效果。
Background: Monocyte chemoattractant protein-1 (MCP-1) is a chemokine locally and systemically augmented in psoriasis. A single nucleotide polymorphism in MCP-1 promoter region -2518A -> G is associated with higher gene expression. Objective: The aim was to evaluate MCP-1 plasma level in psoriatic patients and to relate any association in plasmatic and cutaneous MCP-1 with clinical improvement due to biological drugs. Methods: Blood samples were obtained from: (i) 30 Caucasian patients with psoriasis and 10 controls, for determining MCP-1 plasma concentrations and -2518A -> G polymorphism occurrence, (ii) 16 psoriatic patients treated by anti-tumor necrosis factor-alpha (TNF-alpha) adalimumab/etanercept or by anti-CD-11 efalizumab, before and after 2 months of treatment. Moreover, biopsies were performed on lesional skin of five patients treated with anti-TNF-alpha. MCP-1 plasma concentration and cutaneous expression were determined by ELISA and qRT-PCR. Results: MCP-1 plasma level was significantly increased in psoriatic patients. -2518A -> G polymorphism was similarly distributed in patients and controls and unrelated to MCP-1 plasma level or to Psoriasis Area and Severity Index. All patients receiving biological drugs showed significant clinical improvement. Anti-TNF-alpha therapy moderately reduced MCP-1 plasma concentration and robustly decremented MCP-1 expression in lesional skin. Conclusion: MCP-1 should be a potential local inflammatory marker in psoriatic patients to assess disease severity and anti-TNF-alpha treatment efficacy.